Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$1.49 USD
-0.06 (-4.17%)
Updated Apr 29, 2024 10:11 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
COCP 1.49 -0.06(-4.17%)
Will COCP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for COCP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COCP
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
COCP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for COCP
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
Recap: Cocrystal Pharma Q4 Earnings
Cocrystal Pharma sees cash runway beyond next 12 months